{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-013273","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2024-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.403756+00:00","generated_at":"2026-05-30T14:39:45.513113+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MeiraGTx reports positive Phase 2 data for AAV-GAD in Parkinson's; 18-point UPDRS improvement in high-dose group","bullets":["AAV-GAD met primary safety endpoint; no SAEs related to treatment in 14-patient bridging study.","High-dose group showed 18-point average improvement in UPDRS Part 3 off-medication (p=0.03); sham and low-dose showed no significant change.","PDQ-39 quality-of-life score improved by 8 points (p=0.02) in high-dose and 6 points (p=0.04) in low-dose groups.","100% of high-dose participants reported PDQ-39 improvement vs 60% low-dose and 25% sham.","Company plans to advance AAV-GAD into Phase 3 trial globally; total of 58 patients treated across program with no related SAEs."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-013273","json":"https://secwatch.observer/filing/0001558370-24-013273.json","markdown":"https://secwatch.observer/filing/0001558370-24-013273.md","text":"https://secwatch.observer/filing/0001558370-24-013273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837024013273/0001558370-24-013273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837024013273/mgtx-20241015x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T14:39:45.513113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}